期刊文献+

氟伐他汀对缺血性脑卒中患者的疗效观察及护理措施 被引量:2

Effect and nursing main points of Fluvastatin on patients with cerebral arterial thrombosis
下载PDF
导出
摘要 目的观察不同剂量氟伐他汀对缺血性脑卒中患者的治疗效果并初步总结治疗中的护理措施。方法将85例缺血性脑卒中患者随机分为3组,组①为空白组,组②为常规剂量治疗组,组③为大剂量强化治疗组,进行相关的治疗和护理。于治疗前及治疗4周、12周、24周检测血脂;治疗前和治疗24周时,用德国SEQUOIAS-512型B超测定颈动脉内膜-中层厚度(IMT)记录治疗中出现的副作用等进行比较。结果患者治疗4周、12周、24周血脂试验发现,两个试验组中的LDL、TC、TG下降与空白组比较均有统计学意义(P〈0.05);在治疗24周后,两个试验组可使颈动脉内膜-中层厚度减少(P〈0.05);而且,氟伐他汀的副作用较少,3组间的差异没有统计学意义(P〉0.05)。结论不同剂量氟伐他汀对缺血性脑卒中患者的疗效明显不同,越大剂量的氟伐他汀对缺血性脑卒中患者的LDL~L、TC降低作用越明显、对颈动脉粥样硬化发展的抑制作用就越大,且副作用未见增加。良好的护理,能使患者保持较好的用药依从性、及早发现药物的副作用,从而保证治疗的顺利进行,促进患者早日康复。 Objective To explore the effect and nursing main points of fluvastatin on the patients with cerebral arterial thrombosis. Methods Eighty-five patients with cerebral arterial thrombosis were randomly divided into three groups. Group Ⅰwas the negative control group. Group Ⅱ was the conventional-dose therapy group and group Ⅲ was the high-dose therapy group. Each group was treated with related therapy and care. The blood lipids in all groups were tested before the treatment, 4 weeks, 12 weeks and 24 weeks after the treatment; the carotid intima-media thickness (IMT) were measured by the Germany SEQUOIAS-512-B ultra machine before the treatment and 24 weeks after the treatment; At the same time, the side effects offluvastatin were recorded. Results The results of blood lipid tests showed that the LDL, TC and TG in two treated groups were significantly decreased compared to negative control group (P〈0.05). After treated for 24 weeks, the carotid intima-media thickness (IMT) in two treated groups were significantly reduced (P〈0.05); the side effects offluvastatin were infrequent and there was no significant different among the three groups (P〉0.05). Conclusions The effects of different doses of fluvastatin on cerebral arterial thrombosis were significantly different. With the dose of fluvastatin increased, the serum LDL-L and TC reduced more obvious and the inhibition on carotid atherosclerosis shows more obvious, and the side effects did not increased.
出处 《国际医药卫生导报》 2009年第12期7-10,共4页 International Medicine and Health Guidance News
基金 湛江市科学技术局立项课题(2008C02012)
关键词 氟伐他汀 缺血性脑卒中 疗效 护理 Fluvastatin Cerebral arterial thrombosis Effect Nursing
  • 相关文献

参考文献14

  • 1叶任高,陆再英内科学[M].6版.北京:人民卫生出版社,2007:263-264.
  • 2王传锋,贾明兰.他汀类药物防治动脉粥样硬化的应用[J].中国现代医生,2008,46(10):29-30. 被引量:13
  • 3The SPARCL Investigations.Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study[J].Cerebrovasc DIS,2003,16(4):389-395.
  • 4王苏川,曹宏悦.彩色多普勒超声对脑梗塞患者颈动脉粥样硬化斑块的临床评价[J].中国冶金工业医学杂志,2006,23(3):358-358. 被引量:1
  • 5Corvol J C,Bouzamomdo A,Sirol M,et al.Differential effects of lipid-lowering the rapies on stroke preventions:a metaanalysis of randomized trials[J].Arch Intern Med,2003,163:669-676.
  • 6Amarenco P,Lavallee P,Touboul PJ.Stroke prevention,blood cholesterol,and statins[J].Lancet Neurol,2004,3(5):271-278.
  • 7Albert MA,Danielson E,Rifai N,et al.Effect ofstatin therapy on C-reactive protein levels:the pravastain inflammation/ CRP evaluation (PRINCE):a randomized trial and cohort study[J].JAMA,2001,286(1):64-70.
  • 8Adams HP,Byington RP,Hoen H,et al.Effect of cholesterol-lowering medieations on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke[J].Cerebrovase Dis,1995,5:171-177.
  • 9Sehwarts GG,Olsson AG,Ezekow-itz MD,et al.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.The MIRACL Study:a randomized controlled trial[J].JAMA,2001,285(13):1711~1718.
  • 10陈进,王家良,李宁秀.饮食干预降脂效果——来自“Clinical Evidence”的证据[J].华西医学,2001,16(3):258-260. 被引量:7

二级参考文献21

  • 1李莹,周北凡,武阳丰,郭敏,刘冬海.我国14组中年人群血清胆固醇水平及分布特征[J].中国慢性病预防与控制,1996,4(5):200-201. 被引量:39
  • 2-.卫生部提供WHO有关国内死亡率的资料(1990年)[M].,..
  • 3[1]Raymond CB,Morgan SG,Katz A,et al.A population-based analysis of statin utilization in British Columbia[J].Clin Ther,2007,29(9):2107-2119.
  • 4[2]O' Brien KD.Inflammatory proteins on HDL:what are we measuring[J].Transl Res,2007,150(3):150-152.
  • 5[3]Tziomalos K,Athyros VG,Karagiannis A,et al.Endothelial function,arterial stiffness and lipid lowering drugs[J].Expert Opin Ther Targets,2007,11 (9):1143-1160.
  • 6[4]Hjelstuen A,Anderssen SA,Holme I,et al.Effect of lifestyle and/or statin treatment on soluble markers of atherosclerosis in hypertensives[J].Scand Cardiovasc J,2007,41(5):313-320.
  • 7[5]Virani SS,Nambi V.The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis[J].Curt Atheroscler Rep,2007,9(2):97-103.
  • 8[6]Santiili F,Bucciarelli L,Noto D,et al.Decreased plasma soluble RAGE in patients with hypercholesterolemia:effects of statins[J].Free Radie Biol Med,2007,43(9):1255-1262.
  • 9[7]Vogt A,Kassner U,Hostalek U,et al.Correction of low HDL cholesterol to reduce cardiovascular risk:practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan)[J].Int J Chn Pract,2007,61(11):1914-1921.
  • 10[8]Smilde TJ,van Wissen S,Wollersheim H,et al.Efect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP):a prospective,randomized,double-blind trial[J].Lancet,2001,357(9256):577-581.

共引文献3094

同被引文献27

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部